At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 120 enrolled
Drug / intervention
Fumaderm +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Controlled, Multicenter, Open Label Study With Blinded Assessment of the Efficacy of the Humanized Anti-IL-23p19 Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
In Brief
A Phase 3 clinical trial evaluating Fumaderm and risankizumab for Psoriasis. Completed, enrolled 120 participants across 23 sites.
Detailed Summary
The purpose of this study is to compare the efficacy and safety of subcutaneous (SC) risankizumab and oral FUMADERM provided as study medication in participants with moderate to severe plaque psoriasis who are naïve to and candidates for systemic therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartAug 2017
Primary CompletionJul 2018
TodayJul 2026
First PostedAug 21, 2017
Enrollment StartAug 22, 2017
Primary CompletionJul 6, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.9 years ago
Interventions
Fumadermdrug
Fumaderm tablet administered orally
risankizumabdrug
Risankizumab administered by subcutaneous (SC) injection